Want to see PURE full AI Analyst Report?
PURE Stock Chart & Stats
$0.08
>-$0.01(-8.90%)
At close: 4:00 PM EDT
$0.08
>-$0.01(-8.90%)
Day’s Range― - ―
52-Week Range$0.04 - $0.14
Previous CloseN/A
Volume1.60K
Average Volume (3M)53.72K
Market Cap
$8.11M
Enterprise Value$13.10
Total Cash (Recent Filing)$983.00K
Total Debt (Recent Filing)$6.50M
Price to Earnings (P/E)―
Beta-0.80
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding130,017,560
10 Day Avg. Volume24,352
30 Day Avg. Volume53,720
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-1.96
Price to Sales (P/S)4.56
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary SDC TechnologyOwning a proprietary silver-based SDC antimicrobial platform gives Pure durable product differentiation in sanitation markets. That technology underpins repeatable product sales, supports licensing or formulation leverage, and targets regulated food/institutional end-markets where efficacy drives long-term adoption.
Sustained Revenue RecoveryConsistent TTM revenue growth (~62%) and a multi-year rebound indicate improving commercial traction and demand for SDC products. Durable top-line momentum supports scale opportunities, better fixed-cost absorption, and the potential to narrow losses if growth persists and gross margin quality is sustained.
Recent Financing Bolsters RunwayThe $1.0M private placement, with insider participation, meaningfully extends near-term liquidity for a small company. While modest, this structural financing reduces immediate refinancing pressure, allowing management to execute sales initiatives and work toward self-funding if revenue growth continues.
Bears Say
Persistent UnprofitabilityOperating and net losses in every period show the core business is not yet profitable. Persistent negative earnings undermine reinvestment capacity, increase dependency on external financing, and make long-term viability contingent on consistent margin improvement or sustained capital access.
Negative Shareholders' EquityNegative stockholders' equity signals accumulated deficits and a fragile capital structure. This reduces financial flexibility, can impair borrowing capacity, and raises refinancing or solvency risk if losses persist, making recovery dependent on sustained profits or new equity injections.
Consistent Negative Cash FlowRun-rate negative operating and free cash flow (TTM burn ~-$1.8M) means the business cannot self-fund growth. Reliance on external funding is structural risk; volatile and anomalous cash-flow entries also reduce confidence in sustainability of improvements and complicate planning for 2–6 month horizons.
Pure Bioscience News
PURE FAQ
What was Pure Bioscience’s price range in the past 12 months?
Pure Bioscience lowest stock price was $0.04 and its highest was $0.14 in the past 12 months.
What is Pure Bioscience’s market cap?
Pure Bioscience’s market cap is $8.11M.
When is Pure Bioscience’s upcoming earnings report date?
Pure Bioscience’s upcoming earnings report date is Nov 03, 2026 which is in 81 days.
How were Pure Bioscience’s earnings last quarter?
Pure Bioscience released its earnings results on Jun 15, 2026. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pure Bioscience overvalued?
According to Wall Street analysts Pure Bioscience’s price is currently Overvalued.
Does Pure Bioscience pay dividends?
Pure Bioscience does not currently pay dividends.
What is Pure Bioscience’s EPS estimate?
Pure Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pure Bioscience have?
Pure Bioscience has 130,017,560 shares outstanding.
What happened to Pure Bioscience’s price movement after its last earnings report?
Pure Bioscience reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.857%.
Which hedge fund is a major shareholder of Pure Bioscience?
Currently, no hedge funds are holding shares in PURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pure Bioscience
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; and SILVERION, a SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products. The company serves food processing, food service and hospitality, healthcare, facility care, transportation, and personal care industries. It sells its products through end-use customers and third-party distributors. The company was incorporated in 1992 and is based in El Cajon, California.
Technical Analysis
Mannatech
―
United-Guardian
―
Tantech Holdings
―
Grove Collaborative Holdings
―
Yoshitsu Co. Ltd. Sponsored ADR
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.62% Other Institutional Investors
99.38% Public Companies and
Individual Investors